本文選題：烏司他丁　切入點(diǎn)：重癥肺部感染　出處：《中華醫(yī)院感染學(xué)雜志》2017年19期

【摘要】：目的探討烏司他丁注射液治療重癥肺部感染患者的實(shí)際臨床效果。方法選取2013年9月-2016年9月于醫(yī)院接受治療的86例重癥肺部感染患者為研究對(duì)象,按照隨機(jī)數(shù)表平均分成2組,其中43例患者接受常規(guī)治療方案為對(duì)照組,其余43例患者在常規(guī)治療方案基礎(chǔ)上添加烏司他丁注射液為觀察組,對(duì)患者治療前后進(jìn)行血清檢測(cè),觀察患者腫瘤壞死因子(TNF-α)、C-反應(yīng)蛋白(CRP)及促炎性細(xì)胞因子(IL-18)水平,采用改良患者療效評(píng)價(jià)量表對(duì)患者的治療效果進(jìn)行評(píng)價(jià),對(duì)兩組患者治療后出現(xiàn)不良反應(yīng)的患者進(jìn)行記錄,記錄患者從出現(xiàn)不良反應(yīng)到不良反應(yīng)恢復(fù)的平均時(shí)間,并且記錄患者的平均住院時(shí)間。結(jié)果觀察組患者顯效例數(shù)共26例占60.47%,較對(duì)照組的9例占20.93%,差異有統(tǒng)計(jì)學(xué)意義(P0.05),而對(duì)照組無(wú)效率46.51%較觀察組4.65%,差異有統(tǒng)計(jì)學(xué)意義(P0.05),另外觀察組總有效率為93.35%,對(duì)照組53.49%;兩組患者總不良反應(yīng)例數(shù)對(duì)比無(wú)較大差異,觀察組患者總不良反應(yīng)率為41.86%,而對(duì)照組為39.53%;此外,患者出現(xiàn)了不良情況后,觀察組患者不良情況恢復(fù)時(shí)間為(5.68±1.20)天,住院時(shí)間為(12.68±3.21)天,對(duì)照組患者恢復(fù)時(shí)間為(9.35±2.15)天,住院時(shí)間為(19.51±3.54)天,則說(shuō)明患者不良情況恢復(fù)較好。結(jié)論烏司他丁注射液治療重癥肺部感染患者中有顯著效果,且無(wú)發(fā)現(xiàn)并發(fā)癥等嚴(yán)重病癥,患者出現(xiàn)較少不良反應(yīng),且出現(xiàn)不良反應(yīng)后患者恢復(fù)速度較快、住院時(shí)間較短。
[Abstract]:Objective to investigate the clinical effect of ulinastatin injection in the treatment of patients with severe pulmonary infection. Methods 86 patients with severe pulmonary infection who were treated in hospital from September 2013 to September 2016 were selected as subjects. According to the random number table, 43 patients were divided into two groups, 43 patients received routine therapy as control group, the remaining 43 patients were treated with ulinastatin injection on the basis of routine treatment regimen, and the serum levels were measured before and after treatment. The levels of TNF- 偽 TNF- 偽 C- reactive protein (CRP) and pro-inflammatory cytokine (IL-18) were observed. The therapeutic effect was evaluated by the modified patient evaluation scale. The adverse reactions of the two groups were recorded. The average time from the occurrence of adverse reactions to the recovery of adverse reactions was recorded. Results there were 26 cases of remarkable effect in the observation group (60.47 cases), which was significantly higher than that in the control group (20.93%), and the difference was statistically significant (P 0.05), while the ineffective rate in the control group (46.51%) was higher than that in the observation group (4.65%), the difference was statistically significant. In addition, the total effective rate was 93.35 in the observation group and 53.49 in the control group, and there was no significant difference in the total adverse reactions between the two groups. The total adverse reaction rate in the observation group was 41.86 and that in the control group was 39.53. In addition, the recovery time of the adverse condition was 5.68 鹵1.20 days, the hospitalization time was 12.68 鹵3.21 days, and the recovery time of the control group was 9.35 鹵2.15 days. The duration of hospitalization was 19.51 鹵3.54 days, which indicated that the adverse condition of the patients recovered better. Conclusion Ulinastatin injection has significant effect in treating patients with severe pulmonary infection, and no complications and other serious diseases are found, and the patients have fewer adverse reactions. The recovery rate of patients after adverse reactions was faster and the hospitalization time was shorter.
【作者單位】： 海南西部中心醫(yī)院藥劑科;海南西部中心醫(yī)院呼吸內(nèi)科;儋州市人民醫(yī)院呼吸內(nèi)科;
【分類號(hào)】：R563.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張清君;老年人重癥肺部感染臨床分析[J];臨床肺科雜志;2004年03期

2 孫嵐英;老年人重癥肺部感染150例臨床分析[J];中國(guó)民康醫(yī)學(xué);2005年07期

3 高曉來(lái),陳燕明;泰能治療重癥肺部感染33例療效觀察[J];中國(guó)航天工業(yè)醫(yī)藥;2000年03期

4 卓瑪;;痰熱清佐治肺結(jié)核合并重癥肺部感染療效評(píng)價(jià)[J];中國(guó)中醫(yī)急癥;2006年09期

5 郝建;張益群;彭曉露;陸學(xué)丹;黃媛;趙洪;;重癥肺部感染患者缺氧與肝功能損害的相關(guān)性研究[J];實(shí)用肝臟病雜志;2008年01期

6 楊煒;王瑩;郭華;余果;;經(jīng)纖維支氣管鏡注藥治療重癥肺部感染35例[J];中國(guó)民族民間醫(yī)藥;2009年10期

7 侯終君;;慢性腎臟病應(yīng)用糖皮質(zhì)激素后重癥肺部感染8例臨床分析[J];中國(guó)實(shí)用醫(yī)藥;2009年33期

8 高福生;;纖維支氣管鏡治療重癥肺部感染的應(yīng)用探討[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2010年24期

9 林創(chuàng)輝;陳澤芳;;54例重癥肺部感染的病原學(xué)分析[J];中國(guó)醫(yī)藥指南;2011年04期

10 趙靜;;纖維支氣管鏡在重癥肺部感染治療中的臨床價(jià)值[J];中國(guó)醫(yī)學(xué)創(chuàng)新;2012年14期

相關(guān)會(huì)議論文 前10條

1 汪曄;;纖支鏡吸痰治療重癥肺部感染痰阻病人臨床分析[A];華東地區(qū)第6屆中青年呼吸醫(yī)師論壇暨浙江省第29屆呼吸疾病學(xué)術(shù)年會(huì)論文匯編[C];2007年

2 華鋒;崔恩海;王斌;;粒-巨噬細(xì)胞集落刺激因子在重癥肺部感染機(jī)械通氣中的作用[A];華東地區(qū)第6屆中青年呼吸醫(yī)師論壇暨浙江省第29屆呼吸疾病學(xué)術(shù)年會(huì)論文匯編[C];2007年

3 周瑞祥;翁方中;嚴(yán)駿;范學(xué)朋;;谷氨酰胺和生長(zhǎng)激素強(qiáng)化營(yíng)養(yǎng)對(duì)重癥肺部感染患者免疫調(diào)理作用的臨床觀察[A];首屆全國(guó)中西醫(yī)結(jié)合重癥醫(yī)學(xué)學(xué)術(shù)會(huì)議暨中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)重癥醫(yī)學(xué)專業(yè)委員會(huì)成立大會(huì)論文匯編[C];2010年

4 郭偉;張杰;唐明忠;劉義;張維;楊中華;;保護(hù)性毛刷在肺部重癥感染中應(yīng)用價(jià)值的探討[A];中華醫(yī)學(xué)會(huì)第七次全國(guó)呼吸病學(xué)術(shù)會(huì)議暨學(xué)習(xí)班論文匯編[C];2006年

5 劉加良;;免疫抑制患者(ICH)重癥肺部感染4例[A];華東地區(qū)第6屆中青年呼吸醫(yī)師論壇暨浙江省第29屆呼吸疾病學(xué)術(shù)年會(huì)論文匯編[C];2007年

6 劉加良;;免疫抑制患者(ICH)重癥肺部感染4例[A];2005年浙江省內(nèi)科學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2005年

7 劉加良;;免疫抑制患者(ICH)重癥肺部感染4例[A];2006年浙江省呼吸系病學(xué)術(shù)年會(huì)論文匯編[C];2006年

8 馬凌悅;周穎;;臨床藥師參與1例重癥肺部感染抗感染治療的病例分析[A];2013年中國(guó)臨床藥學(xué)學(xué)術(shù)年會(huì)暨第九屆臨床藥師論壇論文集[C];2013年

9 余紅;葉賢偉;萬(wàn)自芬;徐艷菊;趙麗;張湘燕;;PCT在指導(dǎo)重癥肺部感染抗生素治療中的價(jià)值[A];中華醫(yī)學(xué)會(huì)呼吸病學(xué)年會(huì)——2013第十四次全國(guó)呼吸病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

10 劉加良;;免疫抑制患者(ICH)重癥肺部感染4例[A];2006年浙江省內(nèi)科學(xué)學(xué)術(shù)年會(huì)、2006年浙江省老年醫(yī)學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2006年

相關(guān)碩士學(xué)位論文 前1條

1 胡小劍;腎移植術(shù)后重癥肺部感染危險(xiǎn)及預(yù)后因素分析[D];暨南大學(xué);2013年

，

本文編號(hào)：1684371